CalcMyPeptide
Weight ManagementAlso known as: Byetta, Bydureon, Exendin-4, AC2993

Exenatide

Exenatide (Byetta / Bydureon) is the absolute genesis of the modern GLP-1 revolution. Bizarrely discovered within the venomous saliva of the Gila monster (as Exendin-4), it was the first-in-class GLP-1 agonist to hit the market. While its ultra-short half-life initially required brutal twice-daily injections, it laid the entire physiological groundwork for the modern era of incretin-based weight loss and diabetic management.

Reviewed by CalcMyPeptide Editorial Team
Last updated: April 2026Evidence: Strong1 peer-reviewed citation

Quick Stats

Half-Life~2.4 hours (IR); ~2 weeks release (ER)
Dose Range5-10 mcg twice daily (Byetta) or 2 mg weekly (Bydureon)
Frequency2× daily (IR) or 1× weekly (ER)
Vial Sizes0.25 mg, 2 mg
Bioavailability~100% (SC)
Year Developed2005

Scientific Data

Molecular Formula
C184H282N50O60S
Molecular Weight
4186.6 g/mol
CAS Number
141732-76-5
PubChem ID
45369769
Developer
Alkermes / AstraZeneca (exendin-4 discovery: John Eng, 1992)

Mechanism of Action

Exenatide (Byetta® / Bydureon®) was the first GLP-1 receptor agonist approved by the FDA (2005). It is a synthetic version of exendin-4, a peptide found in the Gila monster lizard's saliva that has 53% homology to human GLP-1. Exenatide acts on GLP-1 receptors to enhance glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The extended-release version (Bydureon BCise) uses microspheres for once-weekly administration. Weight loss averages 2-4 kg versus semaglutide's 15-17%.

Source: PMID: 15765106 (AC2993 Phase 3)

Dosing Protocol

Typical Dose5-10 mcg twice daily (Byetta) or 2 mg weekly (Bydureon)
Frequency2× daily (IR) or 1× weekly (ER)
Half-Life~2.4 hours (Byetta) / ~2 weeks (Bydureon ER)
Common Vial Sizes0.25 mg, 2 mg

Dosing Protocols

Immediate-Release (Byetta)

Dose
5 mcg, then 10 mcg
Frequency
Twice daily (SC, within 60 min before meals)
Note: 5 mcg for 4 weeks, then 10 mcg if tolerated.

Extended-Release (Bydureon)

Dose
2 mg
Frequency
Once weekly (SC)
Note: Weekly microsphere injection. Do not crush or mix with other medications.

Administration

Route
Subcutaneous injection (abdomen, thigh, or upper arm)
Timing
IR: Within 60 min before morning and evening meals. ER: Any time, same day each week.
Fasting Required?
No — food timing not critical

Expected Timeline

Weeks 1-4
Postprandial glucose improvement. Appetite reduction begins.
Months 3-6
Average HbA1c reduction of 0.8-1.1%. Modest weight loss 2-4 kg.

Who Is It For?

Type 2 Diabetes

High

FDA-approved. First-in-class GLP-1 agonist — well-established safety profile since 2005.

Weight Management

Moderate

Modest weight loss. Largely superseded by semaglutide and tirzepatide for weight primary goals.

Reconstitution Example

Vial
2 mg
Water
0.65 mL
Concentration
3.08 mg/mL
Per Unit (100u syringe)
30.8 mcg
Dose of 5 mcg = 0.2 units on a 100-unit insulin syringe
🧮 Calculate Your Exact Exenatide Dose →

Safety & Considerations

FDA-approved. Pancreatitis risk — discontinue and do not restart if suspected. MTC/MEN 2 contraindication (class effect). Common: nausea, vomiting, diarrhea. Injection site nodules with extended-release form.

Regulatory & Legal Status

FDA Status (US)
Research Only
WADA Status (2026)
Not Listed

Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.

Classification

Research Chemical

US Compounding: Not eligible / not available

⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.

Dosing Quick Reference

Exenatide— Dosing Guide
Dose Range
5-10 mcg twice daily (Byetta) or 2 mg weekly (Bydureon)
Half-Life
~2.4 hours (Byetta) / ~2 weeks (Bydureon ER)
Frequency
2× daily (IR) or 1× weekly (ER)
Route
Subcutaneous
0.25 mg vial2 mg vial
💧 0.65 mL BAC water📐 3.08 mg/mL concentration💉 30.8 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com

Frequently Asked Questions

Is exenatide still used when semaglutide exists?▼
Yes, primarily in patients with established tolerability, cost/insurance considerations, or where injectable twice-daily dosing is preferred. Semaglutide and tirzepatide significantly outperform exenatide on weight loss.
What is the difference between Byetta and Bydureon?▼
Byetta is immediate-release exenatide (twice daily). Bydureon is extended-release exenatide in microspheres (once weekly). Bydureon provides more stable glucose control with one injection per week.

References

  1. Blonde L et al. “"Exenatide (exendin-4) in the treatment of type 2 diabetes".” Clinical Therapeutics (2006). PMID: 16860174

📚 Related Articles

GLP-1 Dose Escalation Guide: Semaglutide, Tirzepatide & Retatrutide
14 min read • Pillar Guide

Looking for a trusted source? See our recommended suppliers →

Independently tested · COA-verified · Save 10% with our exclusive code

← Back to Peptide Library